P2D Bioscience has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute. The purpose of this grant is to develop a novel class of anti-inflammatory drugs specifically targeting lung diseases, including acute lung injury/acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma. Click here to read the entire release. […]
P2D Bioscience has received a $1.5 million grant from the National Institutes of Health (NIH) to develop its lead dopamine transport inhibitor, PD2007, through IND safety and toxicology studies for future use in humans. More than a decade of preclinical testing and numerous scientific publications indicate PD2007’s efficacy at inhibiting dopamine transport in multiple brain […]
TeamDynamixHE released version 7.1 of its web-based higher education project and portfolio management software. The latest software update focuses on improving the user experience with a customizable project request workflow system and social collaboration feeds integrated throughout the application. Version 7.1 also integrates TeamDynamixHE’s ticket management system (ITSM) with projects in portfolios. This release includes […]
Etegent Technologies has entered into a sponsorship agreement with The Citizens Motorcar Company, America’s Packard Museum in Dayton, Ohio. The company’s donation allowed the museum to enhance the marine and aviation engine exhibit, including the construction of new engine stands, signage and lighting. As a result of the sponsorship, the exhibit will now be known […]
P2D Bioscience’s lead compounds, PD2005 and PD2007, have received U.S. and Canadian patent protection for treating Attention Deficit/Hyperactivity Disorder (ADHD). The patents contain ADHD-use claims for the entire family of P2D’s first-in-class dopamine transport inhibitors, including PD2005 and PD2007. Click here to read entire release Tweet
